scholarly journals Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Yule Xu ◽  
Ao Rong ◽  
Yanlong Bi ◽  
Wei Xu
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Laser Photocoagulation ◽  
Combined Therapy ◽  
Real Life ◽  
Significant Difference ◽  
Diffuse Diabetic Macular Edema ◽  
The Mean ◽  
Clinical Records ◽  
Number Of Injections

Purpose. To evaluate the efficacy of intravitreal conbercept (IVC) plus modified grid laser photocoagulation (MGP) versus IVC alone for treatment of diffuse diabetic macular edema (DDME).Methods.In this retrospective study, 51 DDME patients were treated with either IVC alone (IVC group) or IVC plus MGP (combined group) with 12 months of follow-up. The clinical records of those patients were reviewed.Results.26 patients (31 eyes) received IVC alone and 25 patients (30 eyes) received combined therapy. At month 12, the mean best-corrected visual acuity (BCVA) letter score improvement was9.1±4.5and7.5±4.2in the IVC group and the combined group and the mean central retinal thickness (CRT) reduction was 145.1 ± 69.9 μm and168.5±53.6 μm, respectively. There was no statistically significant difference of improvement in BCVA (P=0.164) and decrease in CRT (P=0.149) between the two groups. The mean number of injections delivered was significantly higher (P<0.001) in the IVC group (5.6 ± 0.8 per eye) than in the combined group (3.3±1.2per eye).Conclusions. IVC alone or combined with MGP appeared to be effective for treatment of DDME, achieving the similar clinical efficacy. Moreover, MGP helps to reduce the number of injections.

scholarly journals Our 2-Year Real-Life Outcomes in Patients Who Received Ranibizumab Treatment for Diabetic Macular Edema (DME)

2020 ◽  
Author(s):  
İsmail Umut Onur ◽  
Mehmet Fatih Asula ◽  
Ulviye Yiğit ◽  
Ozan Sonbahar ◽  
Utku Furuncuoğlu
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Real Life ◽  
First Year ◽  
Life Outcomes ◽  
Intravitreal Ranibizumab ◽  
Significant Difference ◽  
The Mean ◽  
Second Year ◽  
Change In Mean

Objective: To assess the real-life performance and clinical outcomes in patients with diabetic macular edema (DME). Method: The chart records were retrospectively evaluated for 42 eyes of 42 patients with DME, who were followed for two years between October 2013 and October 2016 at the Retina Unit. The patients were treated using intravitreal ranibizumab (0.5 mg/0.05 ml) for two years. Results: The Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score indicated BCVA values of 71.1±22.4 letters at baseline, 74.1±19.1 letters at the sixth month, 76.2±16.2 letters at the first year, and 76.1±21.2 letters at the end of the second year. BCVA at the sixth month and first and second years were not significantly different from the baseline value (p=0.172, p=0.051, p=0.108). The mean CFT were 407.4±140.0 μm at the baseline, 375.5±141.5 μm at the 6th month, 357.0±129.1 μm at the 1st year, and 313.8±108.9 μm at the end of 2nd year. The change in mean CFT compared to the baseline value was not statistically significant at the 6th month, but were statistically significant at the 1st and the 2nd years (p=0.082, p=0.040, and p=0.000, respectively).The mean numbers of injections and follow-ups at the end of the second year were 3.7±2.5 and 9.1±3.1, respectively. Conclusion: The BCVA did not change significantly compared to baseline. The BCVA eye scores improved by 15 or more letters, in agreement with findings of other multi-center studies. However, the eyes with a BCVA loss of 15 or more letters showed a significant difference, which might reflect the smaller number of injections given in the present study compared to the other studies.

Efficacy of Intravitreal Triamcinolone after or Concomitant with Laser Photocoagulation in Nonproliferative Diabetic Retinopathy with Macular Edema

2009 ◽  
Vol 19 (4) ◽  
pp. 630-637 ◽  
Author(s):  
Erdinc Aydin ◽  
Helin Deniz Demir ◽  
Huseyin Yardim ◽  
Unal Erkorkmaz
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Laser Photocoagulation ◽  
Control Group ◽  
Clinical Effects ◽  
Intravitreal Triamcinolone ◽  
Nonproliferative Diabetic Retinopathy ◽  
Significant Difference ◽  
Group 3 ◽  
The Mean

Purpose To investigate the clinical effects and outcomes of intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) after or concomitant with macular laser photocoagulation (MP) for clinically significant macular edema (CSME). Methods Forty-nine eyes of 49 patients with nonproliferative diabetic retinopathy and CSME were randomized into three groups. The eyes in the laser group (n=17), group 1, were subjected to MP 3 weeks after IVTA; the eyes in the IVTA group (n=13), group 2, were subjected to MP, concomitant with IVTA; the eyes in the control group (n=19), group 3, underwent only IVTA application. Visual acuity (VA), fundus fluorescein angiography, and photography were performed in each group. Results In the first group, the mean VA improved from 0.17±0.09 at baseline to 0.28±0.15 (p=0.114) and in the second group, deteriorated from 0.19±0.08 at baseline to 0.14±0.08 at the sixth month (p=0.141), respectively. In Group 3, the mean VA improved from 0.16±0.08 at baseline to 0.28±0.18 (p=0.118) at the end of the follow-up. When VA was compared between the control and study groups, significant difference was detected at the sixth month (p=0.038). Conclusions MP after IVTA improved VA, rather than MP concomitant with IVTA, and only IVTA application for CSME. MP after IVTA may reduce the recurrence of CSME and needs further investigations in a longer period.

Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema

Ophthalmology ◽  
2013 ◽  
Vol 120 (9) ◽  
pp. 1843-1851 ◽  
Author(s):  
David G. Callanan ◽  
Sunil Gupta ◽  
David S. Boyer ◽  
Thomas A. Ciulla ◽  
Michael A. Singer ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Laser Photocoagulation ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Diffuse Diabetic Macular Edema

scholarly journals Real-world outcomes of two-year Conbercept therapy for diabetic macular edema

2021 ◽  
Vol 14 (3) ◽  
pp. 416-422
Author(s):  
Yong Cheng ◽  
◽  
Ming-Wei Zhao ◽  
Tong Qian ◽  
◽  
...  
Keyword(s):  
Visual Acuity ◽  
Adverse Events ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Retinal Thickness ◽  
Corrected Visual Acuity ◽  
The Mean ◽  
Number Of Injections ◽  
Best Corrected Visual Acuity

AIM: To evaluate the two-year outcomes of patients treated for diabetic macular edema (DME) with intravitreal Conbercept (IVC). METHODS: The clinical data of 30 DME patients (36 eyes) were retrospectively reviewed. The patients were treated with IVC for 3mo. Additional IVC was given at subsequent monthly visits, if needed (3+PRN). The patients were followed up for 24mo. RESULTS: The best-corrected visual acuity (BCVA) at 24mo significantly increased (66.7±15.3 letters) in comparison with the baseline (54.4±15.4 letters, P<0.0001). The mean improvement in BCVA was 11.0±2.9 letters. At 24mo, 44.1% of the eyes surveyed gained ≥15 letters, 52.9% of the eyes gained ≥10 letters, and 70.6% of the eyes gained ≥5 letters. No vision loss was noted in 96.8% of the eyes, and 5.9% of the eyes lost ≥5 letters, but ≤10 letters. The central retinal thickness (CRT) at 24mo was significantly reduced (277.1±122.9 μm) in comparison with the baseline (510.9±186.1 μm, P<0.0001). At 24mo, 43.3% of the patients had a CRT ≤250 μm. The mean number of injections over 24mo was 10.6±2.0. No severe eye or systemic adverse events related to either the drug or injection were noted. CONCLUSION: IVC is safe and effective for the treatment of DME.

scholarly journals CHOROIDAL THICKNESS IN PATIENTS WITH DIABETIC MACULAR EDEMA

2021 ◽  
Vol 71 (2) ◽  
pp. 433-37
Author(s):  
Amash Aqil ◽  
Muhammad Moin ◽  
Khadijah Abid ◽  
Ahsan Mehmood
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Choroidal Thickness ◽  
Macular Thickness ◽  
Control Group ◽  
Central Macular Thickness ◽  
Department Of Ophthalmology ◽  
Significant Difference ◽  
The Mean

Objective: To evaluate central macular thickness and choroidal thickness in patients with macular edema due to diabetic retinopathy versus controls. Study Design: Cross-sectional comparative study. Place and Duration of Study: Department of Ophthalmology, Lahore General Hospital, Lahore, from Jan to Jul 2018. Methodology: A retrospective data of 100 eyes from 50 patients having with diabetic macular edema associated with diabetic retinopathy was extracted from hospital registry. Additionally, 100 eyes of 50 individuals without any preexisting ocular conditions, comprising a control group was included in the study. Choroidal thickness measurements were made from the posterior edge of the retinal pigment epithelium to the choroid/sclera junction at subfoveal level using optical coherence tomography. Central macular thickness was also measured for all the enrolled patients. Results: One hundred patients fulfilling the inclusion criteria were enrolled in our study. The mean age was 56.27 ± 14.41 years. The mean Central macular thickness of all the patients were reported as 270.49 ± 72.38 μm, while the choroidal thickness was 284.89 ± 96.51 μm. There was statistically significant difference in central macular thickness between both healthy and diabetic retinopathy with diabetic macular edema groups (p=0.001), whereas insignificant difference existed between the two groups forchoroidal thickness (p=0.735). Conclusion: In patients with diabetic macular edema no significant change in choroidal thickness was observed compared with healthy controls, while the thickness of the retina was high in patients with macular edema due to diabetes.

Sign in / Sign up

Export Citation Format

Share Document